Trevi Therapeutics Announces Conference Call for Q1 2025 Results

Trevi Therapeutics to Share Financial Results and Updates

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a biopharmaceutical company focused on developing innovative therapies, has scheduled a conference call and an audio webcast. This session will allow the company to present its first quarter 2025 financial results as well as important corporate updates.

Details of the Upcoming Conference Call

The conference call is set for Thursday evening at 4:30 p.m. ET. Participants can join by dialing the domestic number (877) 870 4263, with an alternative international option at (412) 317 0790. No access code will be needed for those joining the call.

How to Access the Webcast

Investors and interested parties can also access the live audio webcast from the 'Investors & News' section of Trevi Therapeutics’ official website. An archived version of the conference call will be available for replay for a period of 30 days following the event.

About Trevi Therapeutics and Its Innovative Approach

Trevi Therapeutics is making strides in the development of Haduvio™, an investigational therapy designed for the treatment of chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). This product represents a significant advancement in addressing chronic cough, a prevalent and debilitating condition for many patients.

The Impact of Chronic Cough on Patients

Chronic cough is not only a frequent symptom found in IPF patients but also a troubling condition affecting many lives. Around 85% of individuals with IPF experience chronic cough, leading to potential complications such as disease progression and reduced quality of life. Furthermore, patients may find themselves coughing excessively — up to 1,500 times a day — which can adversely impact social interactions and daily activities.

Overview of Haduvio™ and Its Mechanism of Action

Haduvio™ is designed to modulate the cough reflex through innovative pathways. As a kappa agonist and a mu antagonist, it acts on the brain and peripheral systems, targeting opioid receptors that are crucial in managing cough. Notably, nalbuphine, its active ingredient, is not classified as a controlled substance by the U.S. Drug Enforcement Agency.

Understanding Refractory Chronic Cough

Refractory chronic cough is characterized by a cough lasting over eight weeks, despite patients receiving treatment for underlying conditions like asthma or gastroesophageal reflux disease. It affects 2 to 3 million individuals in the U.S., presenting substantial challenges not just for patients but also for their families and caregivers.

Future Outlook for Trevi Therapeutics

As the FDA and other regulatory bodies continue to evaluate therapies for chronic cough, Trevi remains committed to its mission of developing effective treatments for patients. Their ongoing trials and the promising results from Haduvio™ could pave the way for approval and availability of new treatment options for those suffering from chronic cough.

Frequently Asked Questions

What is the focus of Trevi Therapeutics?

Trevi Therapeutics is focused on developing innovative therapies, particularly for chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.

When will Trevi report its financial results?

The financial results for the first quarter of 2025 will be shared on May 8, 2025, during a conference call at 4:30 p.m. ET.

How can I participate in the Trevi conference call?

You can join the conference call by calling the provided numbers or by accessing the webcast on Trevi Therapeutics’ website.

What is Haduvio™?

Haduvio™ is an investigational therapy aimed at reducing cough frequency, developed specifically for chronic cough in IPF and RCC patients.

What are the statistics about chronic cough in IPF patients?

Chronic cough impacts around 85% of the IPF population, causing significant disruptions in their lives and health.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.